Biotech traders delivered a blunt verdict: a remarkable response rate is not the same thing as a de-risked investment. Tango Therapeutics shares fell 13% after the company reported an 82% response rate in pancreatic cancer patients treated with its vopimetostat alongside Revolution Medicines' daraxonrasib.

That market reaction matters because it cuts through the headline. The data involved just 22 patients with pancreatic ductal adenocarcinoma, or PDAC, one of the most difficult cancers to treat. Tango characterized the results as results that “surpass any published PDAC datasets,” but investors appeared unwilling to assign full credibility to a result drawn from such a limited sample.

The disconnect is classic biotech trading. A strong early efficacy figure can attract attention, yet the market often asks a more demanding question: how much confidence does the dataset justify? In this case, the answer appears to have been “not enough” to support the share price, at least on the day of the announcement.

Why the 82% figure did not carry the stock

An 82% response rate among 22 patients is undeniably eye-catching. But a small sample can make any percentage vulnerable to statistical noise and patient-selection concerns. Each individual outcome carries substantial weight when the group is this limited. That does not invalidate the result; it means investors may view it as an important signal rather than a confirmed conclusion.

The setting adds another layer of caution. PDAC has proved notoriously difficult to treat, which raises the burden of proof for combination-therapy headlines. Results that look exceptional in a small group still have to establish whether the apparent benefit can hold across a broader and more varied patient population. The assignment provides no additional clinical endpoints, trial-phase information, or regulatory milestones, leaving the response rate as the central disclosed data point.

That limitation may help explain the selloff. Markets do not price headlines in isolation. They price the durability, reproducibility, and commercial significance that may eventually follow. With only 22 patients disclosed, investors may have decided that the data were promising but not yet sufficient to eliminate the clinical uncertainty surrounding the approach.

The trader's lesson in combination-therapy headlines

The episode is a useful warning for anyone trading early-stage biotechnology news. Combination therapies can generate powerful headlines because two mechanisms may appear to work better together than alone. Yet the same complexity can make the evidence harder to interpret. The market may question which component is driving the response, whether the result is reproducible, and how much confidence a small dataset can support.

Tango's partnership context also places the result under a wider spotlight. The reported regimen combines Tango's vopimetostat with Revolution Medicines' daraxonrasib, making the outcome relevant to both companies' narratives. Still, the disclosed result remains a 22-patient observation—not a guarantee that the response rate will persist.

Historical biotech trading offers a familiar parallel: spectacular early data can produce excitement, but skeptical capital often returns when sample size and disease complexity become the focus. Tango's 13% decline indicates that investors were emphasizing uncertainty over headline magnitude. That is not necessarily a judgment that the science has failed. It is a reminder that markets can distinguish between an encouraging signal and evidence strong enough to command conviction.

For traders, the immediate takeaway is straightforward. An 82% response rate may support a bullish scientific narrative, but the small patient population and challenging PDAC setting leave room for skepticism. As the reported market reaction illustrates, early-stage combination-therapy data can be treated as a starting point for scrutiny rather than a final answer.